Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution

Phase 1

Completed

Conditions: Bioavailability
Healthy Subjects

Interventions: Drug: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
Drug: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
Drug: Naloxegol 25 mg (10 mL oral solution)
Drug: Naloxegol 25 mg tablet, given orally

First Posted Date: 2015-05-18

Last Posted Date: 2017-03-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT02446171

Locations: 🇩🇪
Research Site, Berlin, Germany

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase 4

Completed

Conditions: Metastatic Breast Cancer
Locally Advanced or

Interventions: Drug: Fulvestrant

First Posted Date: 2015-05-18

Last Posted Date: 2021-09-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 83

Registration Number: NCT02447328

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

ICS/LABA Adherence and COPD Exacerbation

Completed

Conditions: Pulmonary Disease
Chronic Obstructive

Interventions: Other: Non-Interventional Study

First Posted Date: 2015-05-15

Last Posted Date: 2016-10-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 10000

Registration Number: NCT02446041

Locations: 🇺🇸
Research Facility, Wilmington, Delaware, United States

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: AZD9291

First Posted Date: 2015-05-13

Last Posted Date: 2025-05-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 171

Registration Number: NCT02442349

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

Phase 1

Completed

Conditions: Bioequivalence
Healthy Japanese Subjects
Pharmacokinetics

Interventions: Drug: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Drug: Ticagrelor OD tablet (90 mg single dose) administered without water
Drug: Ticagrelor IR tablet (90 mg) administered with 150 mL of water

First Posted Date: 2015-05-07

Last Posted Date: 2017-01-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 51

Registration Number: NCT02436577

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Phase 3

Completed

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)

Interventions: Drug: Rosuvastatin 20mg

First Posted Date: 2015-05-05

Last Posted Date: 2018-02-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 9

Registration Number: NCT02434497

Locations: 🇨🇳
Research Site, Taipei City, Taiwan

Rosuvastatin Adherence App Study in China

Not Applicable

Completed

Conditions: Dyslipidemia
Hyperlipidemia

Interventions: Other: Smart phone based patient support tool

First Posted Date: 2015-05-04

Last Posted Date: 2019-01-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 885

Registration Number: NCT02433288

Locations: 🇨🇳
Research Site, Wuhan, China

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Paclitaxel
Drug: Olaparib

First Posted Date: 2015-04-30

Last Posted Date: 2019-07-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT02430311

Locations: 🇨🇳
Research Site, Hangzhou, China

Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Completed

Conditions: Acute Coronary Syndrome (ACS)

First Posted Date: 2015-04-30

Last Posted Date: 2018-03-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 1066

Registration Number: NCT02430493

Locations: 🇨🇳
Research Site, Zhengzhou, China

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Phase 4

Completed

Conditions: Type II Diabetes

Interventions: Drug: Placebo
Drug: Farxiga
Drug: Metformin
Drug: Insulin

First Posted Date: 2015-04-29

Last Posted Date: 2017-06-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 226

Registration Number: NCT02429258

Locations: 🇺🇸
Research Site, Renton, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy